Molecular theranostics: principles, challenges and controversies. [PDF]
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Currie G.
europepmc +2 more sources
Use of disodium pamidronate bisphosphonate in patients with bone metastases of lung cancer [PDF]
Disodium pamidronate (Aredia®), a drug of the bisphosphonate group, was administered to 20 patients with pains in the bones due to secondary deposits of lung cancer.
Ranković Boško, Mrđa Vladimir
doaj +1 more source
Complex regional pain syndrome type I (CRPS I)—or algodystrophy—is a rare disease that usually occurs after a traumatic event. It is characterized by typical clinical findings such as severe and disabling pain disproportionate to the injury, functional ...
Antimo Moretti+6 more
doaj +1 more source
Effectiveness and safety of pamidronate treatment in nonambulatory children with low bone mineral density [PDF]
Purpose Nonambulatory pediatric patients may have low bone mineral density (BMD) and increased risk of pathologic fractures. Though bisphosphonate therapy is the mainstream medical intervention in these children, clinical data regarding this treatment ...
Myeongseob Lee+7 more
doaj +1 more source
Comparison of 18F-NaF Imaging, 99mTc-MDP Scintigraphy, and 18F-FDG for Detecting Bone Metastases
Bone is a common metastasis site in several malignancies, most importantly prostate and breast cancers. Given the significance of the early and accurate diagnosis of bone metastases for preliminary staging, treatment planning and monitoring, restaging ...
Habibollah Dadgar+7 more
doaj +1 more source
DIPHOSPHONATES IN PAGET'S DISEASE
Abstract The diphosphonate, sodium etidronate (disodium ethane-1-hydroxy-1,1-diphosphonate) (E.H.D.P.), which inhibits the growth and dissolution of calcium phosphate crystals in vitro, was given at doses of 0, 1, 5, 10, or 20 mg. per kg. per day for up to 6 months to forty-seven patients with Paget's disease of bone.
Russell, R+4 more
openaire +3 more sources
Strontium Ranelate Elevates Expression of Heme Oxygenase-1 and Decreases Alveolar Bone Loss in Rats
Objectives: The purpose of this study was to determine the effects of strontium ranelate on ligature-induced periodontitis in rats and assess the putative involvement of heme oxygenase-1 (HO-1) pathway in these effects.
Ricardo Basto Souza+6 more
doaj +1 more source
BISPHOSPHONATES RELATED OSTEONECROSIS OF THE JAW IN CANCER PATIENTS – EPIDEMIOLOGICAL STUDY
Aim of the study Medication related osteonecrosis of the jaw (MRONJ) is a severe drug adverse effect, often being diagnosed in an advanced stage. The aim of this epidemiological study was to determine the frequency of MRONJ in cancer patients from ...
George Adrian Ciobanu+8 more
doaj
Multiple Myeloma (Part 2) - Update on The Approach to Bone Disease [PDF]
The increase in life expectancy of the world population has led to a concomitant increase in the prevalence of multiple myeloma (MM), a disease that usually affects the elderly population.
Alex Guedes+2 more
doaj +1 more source
The Rehabilitation of Partially Edentulous Maxilla With Unilateral Zygomatic Implants: A Retrospective Study up to 23 Years Follow-Up. [PDF]
ABSTRACT Objectives This retrospective study aimed to evaluate the clinical outcomes associated with zygomatic implant (ZI) rehabilitation in partially atrophic edentulous maxillae over a mean follow‐up period of more than 10.3 years. Methods All consecutive patients underwent ZI rehabilitation between 1999 and 2020, with a minimum follow‐up period of ...
Fan S+3 more
europepmc +2 more sources